Compile Data Set for Download or QSAR
Report error Found 109 Enz. Inhib. hit(s) with all data for entry = 50013598
TargetCytochrome P450 2C9(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567995(CHEMBL4851471 | US11903936, Compound 20)
Affinity DataIC50: 250nMAssay Description:Inhibition of CYP2C9 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567995(CHEMBL4851471 | US11903936, Compound 20)
Affinity DataIC50: 250nMAssay Description:Inhibition of CYP1A2 (unknown origin) using phenacetin O-deethylation by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567995(CHEMBL4851471 | US11903936, Compound 20)
Affinity DataIC50: 250nMAssay Description:Inhibition of CYP2C19 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567995(CHEMBL4851471 | US11903936, Compound 20)
Affinity DataIC50: 250nMAssay Description:Inhibition of CYP2D6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 1.70E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567995(CHEMBL4851471 | US11903936, Compound 20)
Affinity DataIC50: 1.70E+3nMAssay Description:Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetSubstance-P receptor(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibition of NK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 2.90E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 4.00E+3nMAssay Description:Inhibition of CYP2C19 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 4.00E+3nMAssay Description:Inhibition of CYP2D6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 4.20E+3nMAssay Description:Inhibition of CYP2C19 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 6.30E+3nMAssay Description:Inhibition of CYP2C19 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 6.30E+3nMAssay Description:Inhibition of CYP2D6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 8.50E+3nMAssay Description:Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 1.20E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 1.70E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C8(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 1.83E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 1.90E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin) using phenacetin O-deethylation by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin) using phenacetin O-deethylation by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin) using phenacetin O-deethylation by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin) using phenacetin O-deethylation by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2B6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2B6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2B6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2B6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2B6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2B6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C8(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C8(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567967(CHEMBL4850393 | US11903936, Compound 35)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567966(CHEMBL4850116)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 2.04E+4nMAssay Description:Inhibition of human ERG by QPatch assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567957(CHEMBL4855439)
Affinity DataIC50: 5.00E+4nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567964(CHEMBL4858336 | US11903936, Compound 29)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567964(CHEMBL4858336 | US11903936, Compound 29)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567987(CHEMBL4858118)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567988(CHEMBL4850366)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567989(CHEMBL4854927)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567990(CHEMBL4846297 | US11903936, Compound 8)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567991(CHEMBL4848632 | US11903936, Compound 2)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567992(CHEMBL4846204 | US11903936, Compound 11)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567993(CHEMBL4846174)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567993(CHEMBL4846174)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567994(CHEMBL4864218 | US11903936, Compound 17)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567995(CHEMBL4851471 | US11903936, Compound 20)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567996(CHEMBL4855411)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567997(CHEMBL4851832)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Human)
Medicines For Malaria Venture

Curated by ChEMBL
LigandPNGBDBM50567998(CHEMBL4876457 | US11903936, Compound 26)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human DHODH expressed in Escherichia coli BL21-DE3 using L-dihydroorotate as substrate by steady-state DCIP methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
Displayed 1 to 50 (of 109 total ) | Next | Last >>
Jump to: